Jade reports interim Phase I results of JADE101 for IgAN

Jade Biosciences has reported positive interim data from its Phase I trial studying JADE101, an investigational anti-APRIL monoclonal antibody for IgAN. Key findings show mean IgA reductions of around 70% from baseline, sustained at 12 weeks at the 700mg dose. JADE101’s potency resulted in faster, more durable IgA-lowering compared to first-generation anti-APRIL or dual APRIL/BAFF inhibitors. Credit: Motortion Films / Shutterstock.com. Jade Biosciences has reported positive interim data from its Phase I trial studying JADE101, an investigational anti-A proliferation-inducing ligand (APRIL) monoclonal antibody for immunoglobulin A nephropathy (IgAN). The placebo-controlled, double-blind trial evaluated the tolerability, safety, pharmacokinetics, and pharmacodynamics of…

Source: Clinical Trials Arena